Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Anna Nordenström Clear advanced filters

  • The first CRFR1 antagonist (crinecerfont) to be used for the treatment of congenital adrenal hyperplasia recently received FDA approval. This Clinical Outlook discusses the latest phase III studies in children and adults, as well as how crinecerfont — in combination with glucocorticoid replacement — might change clinical practice and affect long-term co-morbidities.

    • Henrik Falhammar
    • Svetlana Lajic
    • Anna Nordenström
    Comments & Opinion
    Nature Reviews Endocrinology
    Volume: 21, P: 197-198

  • Differences of sex development (DSD) encompass a group of rare congenital conditions characterized by atypical sex development. In this Primer, Flück and colleagues provide insights into our current understanding of rare DSD pathophysiology, its prevalence and diagnosis as well as challenges and controversies related to clinical management.

    • Syed Faisal Ahmed
    • Kate Armstrong
    • Christa E. Flück
    Reviews
    Nature Reviews Disease Primers
    Volume: 11, P: 1-28

  • Differences of sex development (DSDs) comprise a large group of congenital conditions of the urogenital tract and reproductive system. This Consensus Statement summarizes recommendations for clinical indications, diagnosis and management of patients with a DSD.

    • Martine Cools
    • Anna Nordenström
    • Vickie Pasterski
    ReviewsOpen Access
    Nature Reviews Endocrinology
    Volume: 14, P: 415-429